TA-TMA
-
Omeros Sets New Date for YARTEMLEA® Approval Conference Call
Omeros Corporation has rescheduled its conference call to January 7, 2026, at 4:30 p.m. ET to discuss the FDA approval and upcoming U.S. launch of YARTEMLEA® on January 2, 2026. YARTEMLEA® is the first and only treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The call will provide details on this significant milestone.
